الاتحاد الأوروبي - البلغارية - EMA (European Medicines Agency)

astrazeneca ab - osimertinib mesilate - Карцином, недребноклетъчен белодроб - Други противоракови лекарства, инхибитори на протеинкиназы - tagrisso as monotherapy is indicated for:- the adjuvant treatment after complete tumour resection in adult patients with stage ib-iiia non-small cell lung cancer (nsclc) whose tumours have epidermal growth factor receptor (egfr) exon 19 deletions or exon 21 (l858r) substitution mutations- the first-line treatment of adult patients nsclc with activating egfr mutations. - the treatment of adult patients with locally advanced or metastatic egfr t790m mutation-positive nsclc. tagrisso as monotherapy is indicated for:- the adjuvant treatment after complete tumour resection in adult patients with stage ib-iiia non-small cell lung cancer (nsclc) whose tumours have epidermal growth factor receptor (egfr) exon 19 deletions or exon 21 (l858r) substitution mutations. - the first-line treatment of adult patients with locally advanced or metastatic nsclc with activating egfr mutations. - the treatment of adult patients with locally advanced or metastatic egfr t790m mutation-positive nsclc.

الاتحاد الأوروبي - البلغارية - EMA (European Medicines Agency)

ab science - masitinib mesilate - Амиотрофична латерална склероза - Антинеопластични средства - Лечение на страничните амиотрофического склероза.

الاتحاد الأوروبي - البلغارية - EMA (European Medicines Agency)

ab science - masitinib mesilate - Мастоцитозата - Антинеопластични средства - Лечение мастоцитоза.

الاتحاد الأوروبي - البلغارية - EMA (European Medicines Agency)

santen oy - latanoprost, netarsudil mesilate - glaucoma, open-angle; ocular hypertension - Офталмологични - roclanda is indicated for the reduction of elevated intraocular pressure (iop) in adult patients with primary open-angle glaucoma or ocular hypertension for whom monotherapy with a prostaglandin or netarsudil provides insufficient iop reduction.

الاتحاد الأوروبي - البلغارية - EMA (European Medicines Agency)

accord healthcare s.l.u. - leuprorelin mesilate - Простатни неоплазми - Ендокринна терапия - camcevi is indicated for the treatment of hormone dependent advanced prostate cancer and for the treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy.

بلغاريا - البلغارية - БАБХ (Българска агенция по безопасност на храните)

richter pharma ag - Перголида - таблетка - 1.0 mg/таблетка - коне

بلغاريا - البلغارية - БАБХ (Българска агенция по безопасност на храните)

alfasan nederland bv - Перголида - таблетка - 0.5 mg/таблетка - коне

بلغاريا - البلغارية - БАБХ (Българска агенция по безопасност на храните)

alfasan nederland bv - Перголида - таблетка - 1.0 mg/таблетка - коне

بلغاريا - البلغارية - БАБХ (Българска агенция по безопасност на храните)

alfasan nederland bv - Перголида - таблетка - 2.0 mg/таблетка - коне

بلغاريا - البلغارية - БАБХ (Българска агенция по безопасност на храните)

„ВЕТ ПРО КОМЕРС“ ООД - lufenuron, moxidectin, praziquantel - таблетки - 20 mg, 0.6 mg, 10 mg/0.5-2 kg; 40 mg, 1.2 mg, 20 mg/2-8 kg; 160 mg, 4.8 mg, 80 mg/8-16 mg; 320 mg, 9.6 mg, 160 mg/ над 16 кг - котки, кучета